Screener
SG&A at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | — | $20,000 | — |
| Operating expenses | ||||
| Research and development | 51,414 | 22,680 | 84,130 | 42,252 |
| Selling, general and administrative | 9,392 | 6,816 | 20,891 | 14,352 |
| Total operating expenses | 60,806 | 29,496 | 105,021 | 56,604 |
| Loss from operations | (60,806) | (29,496) | (85,021) | (56,604) |
| Other income: | ||||
| Interest income | 4,191 | 2,764 | 8,549 | 5,809 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s SG&A?
- Rapport Therapeutics, Inc. (RAPP) reported SG&A of $9.39M in Q2 2026.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Rapport Therapeutics, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude